Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
New Progress in the Treatment of Asthma by Jiankangyuan: First Patient Enrolled in Phase II Clinical Trial of Innovative GSNOR Inhibitor
Published Time：
2024-11-08
On October 16, Health Yuan's novel S-nitrosoglutathione reductase (GSNOR) inhibitor successfully enrolled its first subject in Phase II clinical trials, marking a key step in exploring new treatment options for moderate and severe asthma.
Asthma Innovation Drug Achieves Key Progress Good safety and significant efficacy
Data shows that this new S-nitrosoglutathione reductase (GSNOR) inhibitor is a new generation of asthma treatment drugs that can precisely regulate the GSNO-SNO molecular pathway, significantly inhibiting inflammatory responses and promoting bronchodilation in asthma patients. Compared with existing treatments, this innovative asthma drug is expected to provide a newer and better treatment option for patients who do not respond well to traditional therapies or whose condition is difficult to control.
Asthma, especially severe asthma, has become a problem that cannot be ignored in the current public health field in China. According to authoritative statistics, the prevalence of asthma in people aged 20 and above in China is 4.2%, with 45.7 million patients, of whom nearly 10% have severe asthma.
Although there are many treatment options for asthma, a large number of patients with severe asthma have not been effectively controlled, and their quality of life is severely restricted. Inhaled therapy is currently the main method of drug administration for asthma, and there is an urgent need for high-quality oral asthma drugs for auxiliary treatment. As a leading asthma inhibitor in domestic research and development, this innovative drug from Health Yuan is expected to reduce the rate of nocturnal acute exacerbations in asthma patients and provide more effective treatment for patients with difficult-to-control conditions. In the future, the successful development of GSNOR drugs will greatly meet the urgent clinical needs.
Preliminary research data show that the drug has shown efficacy comparable to that of montelukast, a mainstream asthma drug on the market, and has shown good safety in Phase I clinical trials in healthy individuals. Referring to the sales of montelukast preparations in the domestic pharmaceutical terminal market in 2023 of nearly 1.8 billion yuan, if this innovative asthma drug is successfully approved for marketing, the future market potential will be considerable.
Focus on Advantageous Respiratory Field Accelerated Layout of Innovative Drug Sector
In recent years, Health Yuan has continued to cultivate its advantageous respiratory field and accelerate the layout of its R&D pipeline, with multiple innovative drugs expected to experience a period of intensive breakthroughs. Currently, the company has 10 varieties and 14 specifications of inhalation preparations, and more than 20 respiratory varieties under research. Health Yuan continues to increase its layout of innovative respiratory drugs, has launched 8 innovative drugs, and has successfully achieved full coverage of asthma and COPD inhalation treatment drugs for existing and research varieties.
Among them, the anti-influenza innovative drug, which has attracted much market attention, was submitted for production in August and is expected to be launched next year. At the same time, another TSLP biological drug for COPD is also progressing smoothly in clinical trials. In addition to the two drugs recently entering Phase II, Health Yuan has five respiratory innovative drugs that have advanced to Phase II and beyond.
Combined with Health Yuan's frequent layout in innovative drugs in recent years, and the company's intention to accelerate its focus on innovative drug projects, Health Yuan's innovative drug pipeline is experiencing a rapid upward trend of quality improvement and expansion. In the future, with the steady progress of clinical research and commercialization of various innovative drugs, Health Yuan's development will usher in a new round of explosive growth.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.